HDL elevators and mimetics--emerging therapies for atherosclerosis

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• High LDL cholesterol, triglycerides, and low HDL cholesterol are key risk factors for coronary heart disease (CHD).
• Current treatments for dyslipidemia inadequately address low HDL cholesterol, representing an unmet medical need.
• Low HDL-C is the most prevalent lipoprotein abnormality in CHD patients, with strong evidence linking it to increased cardiovascular risk.

Purpose of the Study:

• To review key players in HDL metabolism and novel therapeutic targets.
• To discuss emerging 'HDL drugs' that elevate HDL or mimic its function in reverse cholesterol transport (RCT).
• To explore the potential of these therapies in preventing cardiovascular disease.

Main Methods:

• Review of scientific literature on HDL metabolism and therapeutic targets.
• Analysis of drug classes designed to modulate HDL levels or function.
• Discussion of HDL mimetics, including ApoA1 mutants and peptide mimetics.

Main Results:

• Two main classes of HDL-targeting drugs are identified: HDL elevators (e.g., CETP inhibitors, PPAR ligands) and HDL mimetics.
• HDL mimetics, such as ApoA1 mutants and peptide mimetics, are considered fast-acting and may benefit acute coronary syndromes.
• Research has significantly advanced the understanding of HDL metabolism, revealing potential therapeutic targets.

Conclusions:

• Targeting HDL metabolism and function represents a promising therapeutic avenue for cardiovascular disease prevention.
• Further research into HDL-elevating agents and HDL mimetics is warranted.
• These novel approaches address the unmet need for effective treatments for low HDL cholesterol in CHD patients.